ProciseDx

ProciseDx is a U.S.-based in vitro diagnostics company that develops and commercializes a proprietary, automated, point-of-care platform for rapid, lab-quality quantitative diagnostic tests. Its primary focus is therapeutic drug monitoring (TDM) for biologic drugs used in inflammatory bowel disease (IBD)—notably infliximab and adalimumab—as well as assays for C-reactive protein and fecal calprotectin. The ProciseDx analyzer delivers quantitative results in as little as 2–5 minutes using whole blood or stool samples. The platform is FDA-cleared and CE-marked, with commercial availability in the U.S., Europe, and the Middle East. The company’s technology enables immediate, on-site TDM, potentially improving treatment decisions and reducing costs for IBD patients[1][6].